Emmaus Life Sciences, Inc. (EMMA)

Market Cap	3.62M +416.8%
Revenue (ttm)	15.53M +11.0%
Net Income	-6.02M
EPS	-0.10
Shares Out	70.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,138
Open	0.0612
Previous Close	0.0516
Day's Range	0.0516 - 0.0612
52-Week Range	0.0080 - 0.0879
Beta	10.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 33
• Stock Exchange: OTCMKTS
• Ticker Symbol: EMMA

Financial Performance

In 2025, Emmaus Life Sciences's revenue was $12.45 million, a decrease of -25.22% compared to the previous year's $16.65 million. Losses were -$7.49 million, 16.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error